Narissa Kreyer predicts Alterna will conduct a clinical study in adult PKU patients demonstrating AP-003 protein generation and biomarker reduction
“are planning to do a study in people living with phenylketonuria or PKU. These will be adults where we're able to show again the AP003 and the protein generation as well as that biomarker reduction”
→ Read the source episode
Our resolution criterion
disputableAlterna initiates and reports results from a clinical trial in adult PKU patients showing AP-003 restores protein generation and reduces relevant biomarkers
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Laurent Levy predicts Nanobiotics will report randomized phase two lung cancer trial results before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.